5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer

F. Tejada, M. A. Eisenberger, L. A. Broder, M. H. Cohen, R. Simon

Research output: Contribution to journalArticlepeer-review

Abstract

A randomized study was carried out to compare the effect of 5- fluorouracil (5-FU) versus CCNU in the treatment of 18 patients with symptomatic metastatic prostatic cancer who failed to respond to hormonal manipulation. Eighteen of the 19 treatment trials in the study were considered evaluable. This study produced a partial response rate of 25% with 5-FU and the responses have been short in duration. Treatment with a nitrosourea, CCNU, produced partial responses in 40% of the patients. The responses to CCNU have been sustained for periods of from 6 to 10 mth. This study indicates that CCNU may potentially be one of the more active agents in the treatment of patients with metastatic prostatic cancer who have failed to respond to primary hormonal therapy.

Original languageEnglish (US)
Pages (from-to)1589-1590
Number of pages2
JournalCancer Treatment Reports
Volume61
Issue number8
StatePublished - Dec 1 1977
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer'. Together they form a unique fingerprint.

Cite this